LINCOLN, Neb. and HEIDELBERG, Germany, July 1, 2025 /PRNewswire/ — LICORbio, a leading innovator in life science imaging and analytical solutions, today announced the acquisition of SERVA Electrophoresis, a privately held company known for its high-quality electrophoresis reagents, consumables, and workflow instrumentation. The transaction strengthens LICORbio’s position as a comprehensive solutions provider in protein analysis and enhances its commitment to driving innovation in life sciences research.
The acquisition significantly broadens LICORbio’s electrophoresis offerings, allowing the company to deliver an end-to-end workflow with an expanded suite of products tailored to the evolving needs of proteomics researchers worldwide. The integration of SERVA’s proprietary technologies with LICORbio’s industry-leading imaging platforms will provide customers with complete workflow solutions from sample preparation to resolution, to imaging and best in class quantification.
“This acquisition reflects LICORbio’s strategic focus on expanding our core technologies while staying close to the needs of the research community,” said Tom Reslewic, chief executive officer of LICORbio. “By integrating SERVA’s expansive electrophoresis products with our established imaging platforms, we’re enabling more accurate, reproducible, and efficient protein, DNA, and RNA analysis workflows.”
“We’re thrilled to welcome the SERVA team into LICORbio,” said Bambi Reynolds, senior vice president and general manager of LICORbio. “This is more than a product expansion, it’s an opportunity to bring integrated solutions and talented people together who share a commitment to supporting the scientific community. Our teams are energized by the possibilities this integration brings, and we’re excited to build a unified strategy centered on innovation, collaboration and customer outcomes.”
Founded in 1953, SERVA has built a reputation for innovation in gel electrophoresis, offering an expansive catalog of reagents and consumables with robust performance across a wide range of applications. Their technology complements LICORbio’s existing portfolio and aligns with its mission to empower discovery through accessible, high-quality tools.
The acquisition is effective immediately, with integration activities already underway. As part of the acquisition, LICORbio will maintain SERVA’s Heidelberg location, honoring its legacy while scaling support through LICORbio’s global infrastructure. Customers can expect uninterrupted access to SERVA’s full product line, with enhanced service and support and integrated imaging solutions.
About LICORbio
LICORbio is a leading developer of imaging systems and analytical tools that empower scientists to uncover new insights in proteomics, genomics, and cell biology. With a heritage of innovation and a commitment to research excellence, LICORbio delivers trusted solutions that accelerate discovery and reproducibility in the lab.
For more information, visit LICORbio.com.
Media Contact:
Katie Schaepe
Director of Marketing
LICORbio
katie.schaepe@licorbio.com
402-467-0800
SOURCE LICORbio
MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading…
– Revenue of $1,047.8 Million Grows 2.5% – – GAAP Diluted EPS of $0.79 Decreases…
Deeply expands leadership in proteomics and multiomicsCombined capabilities bring high scalability, flexibility, and affordability into protein…
AUSTIN, Texas, Jan. 30, 2026 /PRNewswire/ -- RazorMetrics, a leading innovator in pharmacy cost containment…
NEW YORK, Jan. 30, 2026 /PRNewswire/ -- The New York Stock Exchange (NYSE) provides a…
HENDERSON, Nev., Jan. 30, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national…